



Board member Lars Hedbys takes over as acting CEO of RhoVac on 1 September

RhoVac AB ("RhoVac") announces today, August 26th 2022, that the board has decided to appoint board member Lars Hedbys as acting CEO of RhoVac, starting from September 1, 2022. As previously announced, Anders Måansson submitted his resignation on 15 July and will take up his new position on 1 September.

Gunnar Gårdemyr, chairman of the board: *"As Lars has worked on the board of RhoVac since 2015 and has experience from similar assignments, he is well suited to take over the role of acting CEO at RhoVac during the period until RhoVac's future is decided."*

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-08-2022 08:36 CET.

For further information, please contact:

Gunnar Gårdemyr – Chairman of the board, RhoVac AB
Telephone +46 730 837779
E-mail: info@rhovac.com

On RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has passed the early stages of development. In 2019, patient recruitment began for a larger clinical phase IIb study that included more than 180 patients with prostate cancer. The Top Line results were presented in May 2022. Further data are currently being evaluated. RhoVac is listed on the Spotlight Stockmarket. The share is traded under the ticker RHOVAC. More information is available at www.rhovac.com.